Food-related Quality of Life in Patients With Cancer

An observational study of Breast Cancer and Head and Neck Cancers, run by Hospices Civils de Lyon at 3 sites in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Trial summary

Food plays a fundamental role in quality of life. In patients with cancer psychological burden and treatment-related side effects can impact appetite, taste perception and pleasure of eating, making nutritional management more challenging. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Breast Cancer, Head and Neck Cancers, Gynecologic Cancer
What is being tested?: Self-reported questionnaires and Salivary and sensory tests
Type of treatment: Pill or oral medicine
How many people: 180 participants
Where: 3 sitesFrance
Study dates: Mar 2026to Sep 2027
Phase: Observational
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Study population: Patients with different types of cancer gastrointestinal, breast, gynecologic, head and neck, lung, aged between 18 years or older. Two cohorts are considered: patients under treatment (chemotherapy, targeted therapy, immunotherapy, etc., except patients undergoing head and neck radiotherapy) from at least two months and patients having undergone anticancer treatment having completed it at least 3 months and no more than 12 months before inclusion. The necessary number of patients is 180, 90 patients in each cohort.

Who may be able to join

Patient aged 18 years or older;
Patient with gastrointestinal, breast, gynecologic, head and neck, lung
Patient receiving a cancer treatment (chemotherapy, targeted therapy, immunotherapy, etc.) from at least two months;
Patients having undergone anticancer treatment (chemotherapy, targeted therapy, immunotherapy, etc.) having completed it at least 3 months and no more than 12 months before inclusion;
Patient capable of filling a questionnaire;
Patient having given his free, informed and express consent.

Who cannot join

- Patient having a radiotherapy treatment for a head or neck cancer;
Patient having presented nausea and vomiting during the last 24 hours;
Patient with severe inflammation of the mouth or throat (ulcers, mucus);
Patient with cognitive disorders and memory loss;
Pregnant women or breastfeeding;
Adult under legal protection (guardianship, curatorship).

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Amandine BRUYAS, Dr contact

478861628 ext. +33

amandine.bruyas@chu-lyon.fr

Irina Elena ANTOCHI contact

France3 sites

Hôpital Femme Mère Enfant
Bron
Marie BEGUINOT, Dr, marie.beguinot-cornillon@chu-lyon.fr
Hôpital de la Croix Rousse
Lyon
Amandine BRUYAS, Dr, 478861628 ext. +33, amandine.bruyas@chu-lyon.fr
Hôpital Lyon Sud
Oullins
Benoit YOU, Pr, benoit.you@chu-lyon.fr

Other trials in France

About this study

Official title: Modeling the Influence of Pathological Factors, Oral Symptoms and Sensory Perception on Food-related Quality of Life in Patients With Cancer

Given the central role of food and nutrition in maintaining physical health and psychological well-being, it is essential to better understand the factors that contribute to food-related quality of life in order to improve the quality of life of patients with cancer. Despite the importance of these psychological aspects, current assessments tools do not adequately measure the impact of cancer on the food-related quality of life.

In a study entitled "CANUT-QVA" a specific questionnaire measuring nine dimensions of food related quality of life was developed, allowing for a better understanding of how patients perceive and experience their diet. This instrument consists of 46 items and explores nine dimensions, its use showing a significant decrease in food related quality of life of patients with breast cancer, opening the way for targeted interventions to improve nutritional well being and overall quality of life in cancer patients.

The present study aims to analyse various factors - such as oral health, sensory profile and clinical characteristics - associated with food-related quality of life in patients with cancer (gastrointestinal, head and neck, lung, breast and gynecologic cancer) during or after treatment, in order to develop a predictive model of food related quality of life. The main objective of this project is to identify the population at highest risk, so as to better tailor nutritional interventions for patients with cancer, considering both the type of treatment received and the phase, during or after treatment. The food-related quality of life questionnaire containing 46 items will be used to measure the primary outcome.

Conditions: Breast Cancer, Head and Neck Cancers, Gynecologic Cancer, Gastrointestinal Cancer, Lung Cancer
Being tested: Self-reported questionnaires, Salivary and sensory tests
Keywords: cancer, food, nutrition, perceptions, quality of life related to food
Medical subject headings: Breast Neoplasms, Head and Neck Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Self-reported questionnairesOther
Self-reported questionnaires will be used to asses patient's food-related quality of life (QVA questionnaire), global quality of life (EORTC QLQ-C30 questionnaire), evaluation of oral symptoms and perceptions.
Salivary and sensory testsOther
Objective tests will be performed to measure the salivary quality and quantity and taste and smell perceptions.

Study groups in NCT07437326
Study group	Role	What they receive
Patients under treatment		Patients with cancer (gastrointestinal, breast, head and neck, gynecologic, lung), under treatment from at least two months, receiving active anticancer treatment (chemotherapy, targeted therapy, immunotherapy, etc., except patients undergoing head and neck radiotherapy) in a standard of care program. Receives: Other: Self-reported questionnaires; Other: Salivary and sensory tests
Patients after treatment		Patients who have undergone anticancer treatment (chemotherapy, targeted therapy, immunotherapy, etc.) having completed it at least 3 months and no more then 12 months before inclusion. Receives: Other: Self-reported questionnaires; Other: Salivary and sensory tests

What is being measured

The primary outcome is the main question the study is designed to answer.

The food-related quality of life in patients with cancer (gastrointestinal, breast, head and neck, gynecologic, lung).
The food-related quality of life questionnaire containing 46 items will be used to measure the outcome. The questionnaire uses a Likert scale: 1 = never; 2 = sometimes; 3 = often; 4 = always.
Measured: day of inclusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Mar 2026Sep 2027

First posted27 Feb 2026
Study startMar 2026 (estimated)
Primary completionSep 2027 (estimated)
Study completionSep 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Breast CancerStudies of the same condition, open and under way.
More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Cohort
Time perspective: Prospective
Enrolment: 180 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07437326
Sponsor's protocol ID: 69HCL25_0908
Other IDs: 2025-A02292-47
Acronym: QVA-Mod
Status last verified: Feb 2026
First submitted: 20 Feb 2026
Last updated: 27 Feb 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Interested in taking part?

Amandine BRUYAS, Dr

478861628 ext. +33

amandine.bruyas@chu-lyon.fr

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8

All Breast Cancer trials

Study at a glance

From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Modeling the Influence of Pathological Factors, Oral Symptoms and Sensory Perception on Food-related Quality of Life in Patients With Cancer
ClinicalTrials.gov ID: NCT07437326
Acronym / sponsor ID: QVA-Mod / 69HCL25_0908
Conditions: Breast Cancer, Head and Neck Cancers, Gynecologic Cancer, Gastrointestinal Cancer, Lung Cancer
Keywords: cancer, food, nutrition, perceptions, quality of life related to food
Study type: Observational
Recruitment status: Not yet recruiting
Enrolment: 180 participants (estimated)
Lead sponsor: Hospices Civils de LyonUniversity, hospital or other
Study start: Mar 2026 (estimated)
Primary completion: Sep 2027 (estimated)
Study completion: Sep 2027 (estimated)
First posted: 27 Feb 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Observational model: Cohort
Time perspective: Prospective
Number of arms: 2

Arm	Type	Receives
Patients under treatment	–	Other: Self-reported questionnaires, Other: Salivary and sensory testsPatients with cancer (gastrointestinal, breast, head and neck, gynecologic, lung), under treatment from at least two months, receiving active anticancer treatment (chemotherapy, targeted therapy, immunotherapy, etc., except patients undergoing head and neck radiotherapy) in a standard of care program.
Patients after treatment	–	Other: Self-reported questionnaires, Other: Salivary and sensory testsPatients who have undergone anticancer treatment (chemotherapy, targeted therapy, immunotherapy, etc.) having completed it at least 3 months and no more then 12 months before inclusion.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult
Study population: Patients with different types of cancer gastrointestinal, breast, gynecologic, head and neck, lung, aged between 18 years or older. Two cohorts are considered: patients under treatment (chemotherapy, targeted therapy, immunotherapy, etc., except patients undergoing head and neck radiotherapy) from at least two months and patients having undergone anticancer treatment having completed it at least 3 months and no more than 12 months before inclusion. The necessary number of patients is 180, 90 patients in each cohort.

Key inclusion criteria (6 listed)

Patient aged 18 years or older;
Patient with gastrointestinal, breast, gynecologic, head and neck, lung
Patient receiving a cancer treatment (chemotherapy, targeted therapy, immunotherapy, etc.) from at least two months;
Patients having undergone anticancer treatment (chemotherapy, targeted therapy, immunotherapy, etc.) having completed it at least 3 months and no more than 12 months before inclusion;
Patient capable of filling a questionnaire;

Key exclusion criteria (6 listed)

- Patient having a radiotherapy treatment for a head or neck cancer;
Patient having presented nausea and vomiting during the last 24 hours;
Patient with severe inflammation of the mouth or throat (ulcers, mucus);
Patient with cognitive disorders and memory loss;
Pregnant women or breastfeeding;

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Self-reported questionnairesSelf-reported questionnaires will be used to asses patient's food-related quality of life (QVA questionnaire), global quality of life (EORTC QLQ-C30 questionnaire), evaluation of oral symptoms and perceptions.	Other	Patients after treatment, Patients under treatment
Salivary and sensory testsObjective tests will be performed to measure the salivary quality and quantity and taste and smell perceptions.	Other	Patients after treatment, Patients under treatment

Primary outcome

The food-related quality of life in patients with cancer (gastrointestinal, breast, head and neck, gynecologic, lung).
Time frame: day of inclusion
The food-related quality of life questionnaire containing 46 items will be used to measure the outcome. The questionnaire uses a Likert scale: 1 = never; 2 = sometimes; 3 = often; 4 = always.

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
Individual participant dataSharing planned: No

Related trials for Breast Cancer

Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Amandine BRUYAS, Dr contact

478861628 ext. +33

amandine.bruyas@chu-lyon.fr

Irina Elena ANTOCHI contact

Amandine BRUYAS, Dr principal investigator

Hospices Civils de Lyon

3 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Breast Cancer and Head and Neck Cancers, run by Hospices Civils de Lyon at 3 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Amandine BRUYAS, Dr (478861628 ext. +33, amandine.bruyas@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The food-related quality of life in patients with cancer (gastrointestinal, breast, head and neck, gynecologic, lung). (time frame: day of inclusion). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07437326.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.